ImmunoGen, Inc.: cashflow_financing
| Value | {"amount": 35122000, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2021-01-01 – 2021-06-30 |
| Status | current |
| Entity | ImmunoGen, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T08:28:08.271109+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/2087482b-be2f-449b-97bd-c4fd54b9b6f7
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001558370-21-009731 · Open the official SEC filing →Retrieved: 2026-08-19T08:28:08.271109+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0000855654/cashflow-financing/2021-06-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/2087482b-be2f-449b-97bd-c4fd54b9b6f7
History
- no predecessors — first report